 Editors' picks Permission granted by Biogen Biogen's new Alzheimer's drug Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw. At Morgan Stanley's healthcare conference last week, executives detailed how the launch of their Alzheimer's drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage. By Jacob Bell • Sept. 0, 0000 Adeline Kon/BioPharma Dive Deep Dive Biotech M&A, while far from recent heights, is picking back up. Here are the latest deals. Swiss pharma Vifor is buying Sanifit and its kidney disease drug for $000 million upfront, while Twist Biosciences is adding drug discovery specialist Abveris in a stock-based deal. By Jacob Bell and Julia Himmel • Updated Nov. 00, 0000 